7 results about "Corneal epithelium" patented technology

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

This invention discloses a blueberry anthocyanin nutritional solid composition for relieving eye discomfort. The composition comprises blueberry anthocyanin solid powder, algal oil powder, zinc gluconate, and selenium-enriched yeast, and may optionally contain lipid nutrients containing gamma-linolenic acid, as well as food additives and excipients. Oral administration of this composition provides the body with various nutritional supports related to ocular surface function and ocular moisture, helping to maintain tear secretion levels, improve tear film stability, and support the normal physiological state of the corneal epithelium, thereby relieving eye dryness and discomfort caused by environmental stimuli or increased eye strain. Animal experiments showed that after 14 days of continuous administration of the composition, experimental mice exhibited a significantly increased tear secretion volume compared to the control group without the composition, with an increase of approximately 165%. Corneal fluorescein staining scores were also significantly reduced, indicating improved ocular surface condition and significantly enhanced eye comfort.

The application discloses a kind of drug composition of synergistic targeting MMP-9 path and STING path and application thereof, belong to the technical field of ophthalmic drugs.The drug composition includes the final concentration 5~90 μM of Marimastat, the final concentration 2.5~10 μM of SN-011, the final concentration 0.1 vol % of DMSO and sterile PBS buffer solution.The drug composition of the application can efficiently, safely treat moderate to severe dry eye, effectively improve tear film stability, repair corneal epithelial barrier, inhibit ocular surface chronic inflammation, while reducing the risk of disease recurrence.

The invention relates to a method for providing control data for an ophthalmic laser (12) of a treatment device (10). The method comprises, as steps: determining parameters of an epithelial layer and a stroma of a cornea (16); determining a correction profile (14) for correcting a refractive error of the cornea (16); determining data of a virtual postoperative cornea expected by treating the cornea (16) with the correction profile (14), wherein the data of the virtual postoperative cornea are determined as a function of an epithelial layer model in which epithelial regrowth of the cornea is modeled, wherein model parameters of the epithelial layer model are provided from statistics of epithelial regrowth processes of a given population group;a determination of a correction difference between an originally planned correction and a virtually achieved correction; an adjustment of the correction profile (14) depending on the correction difference; and a provision of the control data for the ophthalmic laser (12) that includes the adjusted correction profile.;

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

The application provides application of KGF-2 in treatment of dry eye, and proves that KGF-2 can improve the basic tear secretion of dry eye mice in a dose-dependent manner, prolong the tear film break-up time, reduce the corneal epithelium and corneal nerve injury, and can reduce the expression levels of inflammatory factors such as tear gland MMP-3, MMP-9 and TNF alpha, and improve the tear secretion function of the tear gland.

Generation of treatment recommendations for topographic-based excimer laser surgical procedures is described that includes generating accurate cylinder compensation and spherical compensation values that are adjusted to compensate for unique characteristics of topographic-based excimer laser surgical systems. Generating treatment recommendations generally includes determining a topographic vector, a posterior astigmatism vector and an anterior astigmatism vector, and generating an internal astigmatism vector using the topographic vector, the posterior astigmatism vector, the anterior astigmatism vector, and a manifest astigmatism vector. In embodiments, the cylinder compensation is generated using multiple vectors while subtracting the internal astigmatism vector and the posterior astigmatism vector which remain in the eye after treatment, and the spherical compensation is generated using an initial spherical compensation modified by addback modifiers and a regression analysis nomogram. In procedures where the corneal epithelium is removed, an epithelial refractive vector is determined from an epithelial thickness / topography map and added to the other vectors.